Provided by Tiger Trade Technology Pte. Ltd.

AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF

24.43
-0.0928-0.38%
Volume:144
Turnover:4K
Market Cap:5.62M
PE:- -
High:24.52
Open:24.52
Low:24.43
Close:24.52
52wk High:27.94
52wk Low:22.89
Shares:230.00K
Float Shares:230.00K
Volume Ratio:0.13
T/O Rate:0.06%
Dividend:0.41
Dividend Rate:1.69%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Hims & Hers Names Jon Franklin as Chief Accounting Officer

THOMSON REUTERS
·
Oct 08

Hims & Hers Names Jonathan Franklin Principal Accounting Officer as Irene Becklund Resigns Role

Reuters
·
Oct 08

Cboe data suggests bullish flow in Novo Nordisk with shares up 1.69%

TIPRANKS
·
Oct 08

Eli Lilly and Co Stock (LLY) Moved Up by 3.94% on Oct 7: Facts Behind the Movement

TradingKey
·
Oct 08

Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis

TradingKey
·
Oct 08

Novo Nordisk A/S Series B Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Oct 08

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Oct 08

Novo Nordisk call volume above normal and directionally bullish

TIPRANKS
·
Oct 07

European Equities Traded in US as ADRs Fall in Wednesday Trading

MT Newswires Live
·
Oct 07

Pharma Lobby Sues Trump Administration over Medicare Drug Price Cuts

Reuters
·
Oct 07

Eli Lilly is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Oct 07

What Eli Lilly Stock's First Line Jaypirca Approval Means For Shareholders

Simply Wall St.
·
Oct 07

Morgan Stanley Adjusts Price Target on Eli Lilly to $1,430 From $1,419

MT Newswires Live
·
Oct 07

AlzeCure Pharma to Present at Redeye Neurology Day

Reuters
·
Oct 07

Deutsche Bank Keeps Their Sell Rating on Novo Nordisk (0QIU)

TIPRANKS
·
Oct 07

Novo Nordisk Probes Patient Priorities in German Hemophilia A Study

TIPRANKS
·
Oct 07

Lilly’s New Basal Insulin Candidate Clears Key Early Trial Milestone

TIPRANKS
·
Oct 07

General Medicine Raises $120 Mln to Build the Healthcare Store

Reuters
·
Oct 06

General Medicine - Series B Financing Led by Andreessen Horowitz (a16z), with Participation from Matrix, Vxi Capital, Eli Lilly and Company

THOMSON REUTERS
·
Oct 06

Viking Therapeutics, Inc.: Reporting Results from Part 2 of Vanquish-1 Study in 2027

THOMSON REUTERS
·
Oct 06